AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.27+4.14 (+1.04%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.27+4.14 (+1.04%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|
22.4 C
New York
Monday, June 29, 2026

Tag: study

Bioma Probiotics Redefines Digestive Health in 2025 With Its Strongest Prebiotic, Probiotic, and Postbiotic Synergy Yet

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.
Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.

Robotic Surgery Market 2025 Trends: Advanced AI Systems, Telesurgery and $400M Investments Power Global Expansion

The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.
The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.

Texas Tech, ACU, Natura Resources Announce Path to Deployment for Nuclear Reactor, Desalination of Produced Water

The Texas Legislature positions Texas as a national and global leader in next-generation nuclear technology, water security and medical research  ABILENE, Texas, July 3, 2025...

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson’s Disease and identifies clear opportunities...

ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Upcycled Materials in Packaging Market Ramps Up in 2025 with ESG Goals and Regulatory Support

According to Towards Packaging consultants, the global upcycled materials in packaging market is expected to witness significant growth during the forecast period from 2025 to 2034. Driven by evolving industry trends, increasing demand, and technological advancements, the market is projected to expand at a steady pace, highlighting its rising importance across various sectors worldwide.
According to Towards Packaging consultants, the global upcycled materials in packaging market is expected to witness significant growth during the forecast period from 2025 to 2034. Driven by evolving industry trends, increasing demand, and technological advancements, the market is projected to expand at a steady pace, highlighting its rising importance across various sectors worldwide.

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson’s Disease and identifies clear opportunities...

ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...

Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises

New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website 

Karolinska Development receives update from Organon concerning OG-6219

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.

Bitget Wraps Up Anti-Scam Month with Over 65% of Participants Successfully Identifying Crypto Fraud Tactics

Bitget ends Anti-Scam Month with 65% of users identifying fraud tactics through gamified tools, reports, and expert insights.

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy